COVID Collaboration

Houston health care organizations team up for the 'people's vaccine'

Texas Children's Hospital and Baylor College of Medicine are working on a new COVID-19 vaccine candidate. Photo by Dwight C. Andrews/Greater Houston Convention and Visitors Bureau

Two major health care institutions in Houston — Texas Children's Hospital and the Baylor College of Medicine — are a step closer to rolling out what they dub the "people's vaccine" for COVID-19.

The two institutions, along with India-based vaccine and pharmaceutical company Biological E Ltd., have gained approval to move ahead this month with Phase III clinicals trials in India of a COVID-19 vaccine candidate called Corbevax. The Texas Children's Hospital Center for Vaccine Development developed the vaccine's protein antigen, which was licensed from the Baylor College of Medicine's BCM Ventures commercialization arm.

Unlike COVID-19 vaccines in the U.S., Corbevax contains the so-called "spike protein" from the surface of the novel coronavirus. Once that protein is injected via a vaccine, the body is supposed to begin building immunity against the protein and thereby prevent serious illness.

Experts envision Corbevax being a readily available weapon in the global fight against the COVID-19 pandemic, thanks to the simple vaccine platform (like the one used to prevent Hepatitis B) and the ability to store the vaccine in normal refrigerated settings. The targets of this vaccine are children and mothers.

"In the midst of India's public health crisis, it is our hope that our Texas Children's and Baylor COVID-19 vaccine can be released for emergency authorization in India and in all countries in need of essential COVID-19 vaccinations," Dr. Peter Hotez, co-director of the Texas Children's Hospital Center for Vaccine Development, says in a June 9 news release.

India has reported more than 29 million cases of COVID-19, causing 354,000 deaths. The country's COVID-19 surge reached its peak in May.

"The vaccines currently available cannot be manufactured quick enough to meet supply shortages in low-income countries," Hotez says. "Our vaccine is truly 'the people's vaccine,' created to serve the most marginalized and underserved populations that are hardest hit by this pandemic. This is the vaccine that could be used to vaccinate the world."

In the Phase III trial, the two-dose Corbevax vaccine will be administered to about 1,200 people age 18 to 80 at 15 sites in India. A larger global study of Corbevax is in the works.

According to India.com, Corbevax could be the most affordable COVID-19 vaccine available in the nation of nearly 1.37 billion people, costing close to $7 for a two-dose regimen. The Indian government already has preordered 300 million doses of Corbevax, which has shown promise in Phase I and Phase II trials. The Phase II trial ended in April.

If the Phase III trial goes as planned, doses could be widely administered as soon as August. Biological E initially plans to produce 75 million to 80 million doses per month, according to media reports. The Indian company foresees manufacturing at least 1 billion doses by the end of 2022.

Trending News

Building Houston

 
 

This autonomous freight delivery provider has entered the Texas market. Photo via VAS

A global car brand has expanded its autonomous transport-as-a-service company to Texas.

Volvo Autonomous Solutions, or VAS, announced it has established an office in Fort Worth to set up its first self-driving freight corridors between Dallas-Fort Worth and El Paso, as well as from Dallas to Houston. Ahead of commercial launch, VAS has started hauling freight for key customers like DHL and Uber Freight for testing purposes.

"At Volvo Autonomous Solutions, we believe the path to autonomy at scale is through reducing the friction and complications around ownership and operations for customers," says Nils Jaeger, president of VAS, in a news release. "This is why we have taken the decision to be the single interface to our customers and take full ownership of the elements required for commercial autonomous transport. With the opening of our office in Texas and start of operational activities, we are building the foundations for a transport solution that will change the way we move goods on highways."

As a part of the Volvo Group, VAS provides its Autonomous Transport Solutions — a combination of hardware, software, and services — to its customers.

"Through our Autonomous Transport Solution, our ambition is to create a new source of industry capacity that will ease some of the burden of the increasing demand for freight while also enabling local drivers to shift into short-haul jobs that will keep them closer to home. This will unlock significant efficiencies in the entire supply chain and benefit everyone in the transportation industry," says Sasko Cuklev, head of On-Road Solutions, in the release.

The company has a partnership with Aurora, which includes the integration of the Aurora Driver with Volvo's on-highway truck offering.

Autonomous freight tech development in Texas has ramped up, with Ikea testing deliveries last fall and Silicon Valley-based Kodiak Robotics entering the Texas market in 2019.

Trending News